Response by Fauchier et al to Letter Regarding Article, “Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?”

In Response:

We thank Zhang et al for their interest in our study reporting a positive net clinical benefit of oral anticoagulation using vitamin K antagonist for preventing stroke and other thromboembolic events in atrial fibrillation patients with only 1 nongender-related stroke risk factor (CHA2DS2-VASc 1 in males or 2 in females).1

Recent trials with non-vitamin K antagonist oral anticoagulant (NOAC) agents provide data for benefit even with at least 1 single stroke risk factor.2 However, these results were obtained in patients using the older CHADS2 score (meaning that their CHA2DS2-VASc score might actually have been higher) and were borderline for significance. Our data suggest that patients with 1 nongender-related should be more widely treated with oral anticoagulation and the NOACs are possibly additional options. Only vitamin K antagonist therapy was used for anticoagulation in our study, and we presume that the data would apply to current therapy with NOACs, which offer efficacy, safety, and relative convenience compared with vitamin K antagonist.2 Indeed, anticoagulation with a new, safer agent, modeled with decision analytic tools, may lead to a lowering of the threshold for anticoagulation to a stroke rate of 0.9% per year.3 The balance between risk factors for stroke, risk of bleeding, and benefit of anticoagulation may also be shifting between NOACs.4,5 Clinical trials performing head-to-head comparisons of these treatments in these patients are improbable but would be the best option to answer these questions.

Disclosures

Dr Fauchier has served as a consultant for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi Sankyo and has been on the speakers bureau from Bayer, BMS/Pfizer, and Boehringer Ingelheim. Dr Lip has served as a consultant for Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo and as a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo. The other authors report no conflicts.

Laurent Fauchier, MD, PhD
Arnaud Bisson, MD
Service de Cardiologie
Centre Hospitalier Universitaire Trousseau et Faculté de Médecine
Université François Rabelais Tours, France

Gregory Y.H. Lip, MD
University of Birmingham Institute of Cardiovascular Sciences
City Hospital
Birmingham B18 7QH
United Kingdom

Response by Fauchier et al to Letter Regarding Article, "Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA_2DS_2-VASc Risk Factor Be Anticoagulated?"
Laurent Fauchier, Arnaud Bisson and Gregory Y.H. Lip

Stroke. 2016;47:e239; originally published online August 11, 2016;
doi: 10.1161/STROKEAHA.116.014619

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/47/10/e239

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/